辐射瘤学的先进实践提供者领导的试验:我们是否错过了机会?
1From The University of Texas MD Anderson Cancer Center, Houston, Texas.
Journal of the advanced practitioner in oncology
|December 5, 2025
概括
先进实践提供者 (APP) 在放射瘤学中至关重要,但在研究领导方面面临障碍. 扩大APP主导的研究,特别是患者报告的结果,需要解决系统性挑战并促进指导.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 患者报告的结果
背景情况:
- 先进实践提供者 (APP) 是放射瘤学团队的重要成员.
- 目前,APP在临床研究领导角色中代表性不足.
- 它们与患者护理的接近为研究提供了独特的见解.
研究的目的:
- 探索APP主导的辐射瘤学研究的障碍和机会.
- 确定增加APP参与临床研究的战略途径.
- 专注于患者报告的结果 (PRO) 和医疗服务研究.
主要方法:
- 文献审查和系统性挑战的分析.
- 探索支持研究的国家倡议.
- 讨论机构支持的战略途径.
主要成果:
- 关键的障碍包括有限的受保护的研究时间,不一致的凭证和缺乏指导.
- 像PROTEUS这样的国家倡议为PRO集成提供了工具和资金.
- 有机会将APP的专业知识与研究重点保持一致.
结论:
- 推进APP主导的研究对于包容性和以患者为中心的放射性瘤学研究至关重要.
- 解决系统性障碍和提供指导是关键的步骤.
- 在研究领导中支持APP可以提高创新和护理质量.
相关概念视频
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


